Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 12:47PM ET
0.5657
Dollar change
-0.0469
Percentage change
-7.66
%
IndexRUT P/E- EPS (ttm)-0.11 Insider Own0.66% Shs Outstand220.42M Perf Week-0.96%
Market Cap124.69M Forward P/E- EPS next Y-0.11 Insider Trans9.03% Shs Float218.96M Perf Month-40.38%
Income-20.11M PEG- EPS next Q-0.03 Inst Own43.57% Short Float8.38% Perf Quarter-37.77%
Sales8.72M P/S14.30 EPS this Y6.94% Inst Trans0.29% Short Ratio12.66 Perf Half Y-39.11%
Book/sh0.35 P/B1.61 EPS next Y4.48% ROA-19.84% Short Interest18.34M Perf Year-40.74%
Cash/sh0.15 P/C3.81 EPS next 5Y- ROE-29.95% 52W Range0.50 - 1.61 Perf YTD-48.10%
Dividend Est.- P/FCF- EPS past 5Y19.25% ROI-29.66% 52W High-64.86% Beta1.16
Dividend TTM- Quick Ratio2.48 Sales past 5Y119.78% Gross Margin87.74% 52W Low13.14% ATR (14)0.06
Dividend Ex-Date- Current Ratio2.48 EPS Y/Y TTM18.15% Oper. Margin-260.70% RSI (14)37.54 Volatility7.80% 10.66%
Employees75 Debt/Eq0.04 Sales Y/Y TTM-0.60% Profit Margin-230.66% Recom1.43 Target Price4.83
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q60.44% Payout- Rel Volume1.60 Prev Close0.61
Sales Surprise265.37% EPS Surprise50.00% Sales Q/Q203.29% EarningsNov 14 AMC Avg Volume1.45M Price0.57
SMA20-11.58% SMA50-27.59% SMA200-42.16% Trades Volume1,228,927 Change-7.66%
Date Action Analyst Rating Change Price Target Change
Aug-20-24Initiated Craig Hallum Buy $4
Nov-02-22Initiated Robert W. Baird Outperform $5
Jun-14-22Initiated B. Riley Securities Buy $4
Aug-19-21Initiated Noble Capital Markets Outperform $8
Mar-31-21Initiated Cantor Fitzgerald Overweight $6
Dec-03-24 02:55AM
Nov-21-24 05:00PM
09:35AM
Nov-20-24 08:00AM
Nov-15-24 04:00PM
05:15PM Loading…
Nov-14-24 05:15PM
04:01PM
Nov-07-24 08:00AM
Oct-14-24 08:00AM
Oct-09-24 05:52PM
12:00PM
Sep-25-24 08:00AM
Sep-18-24 08:00AM
Aug-13-24 08:00AM
Aug-08-24 06:35PM
04:05PM Loading…
04:05PM
Aug-01-24 08:00AM
Jul-02-24 08:00AM
May-30-24 08:00AM
May-21-24 08:00AM
May-10-24 04:40PM
03:49PM
02:09PM
May-09-24 04:01PM
May-06-24 08:00AM
May-02-24 08:00AM
Apr-30-24 08:00AM
Apr-29-24 04:30PM
Apr-19-24 12:13PM
Apr-01-24 08:00AM
10:31AM Loading…
Mar-18-24 10:31AM
08:00AM
Mar-14-24 03:53PM
Mar-13-24 08:00AM
Mar-11-24 08:00AM
Mar-08-24 04:20PM
Mar-07-24 10:36PM
04:01PM
Feb-29-24 08:00AM
Feb-13-24 08:00AM
Feb-09-24 09:15AM
Feb-06-24 09:15AM
Jan-16-24 08:00AM
Dec-18-23 08:00AM
Nov-11-23 04:02PM
Nov-10-23 02:13PM
09:17AM
Nov-09-23 04:01PM
Nov-01-23 08:00AM
Oct-24-23 08:00AM
Oct-17-23 05:14PM
Oct-11-23 08:00AM
Oct-05-23 08:00AM
Sep-19-23 08:00AM
Sep-13-23 08:00AM
Sep-11-23 08:00AM
Sep-06-23 09:40AM
08:00AM
Aug-29-23 08:00AM
Aug-13-23 06:39AM
Aug-11-23 09:43AM
Aug-10-23 05:15PM
04:01PM
Aug-09-23 08:50AM
Aug-08-23 06:40PM
Aug-03-23 08:00AM
Jul-24-23 08:00AM
May-22-23 08:00AM
May-16-23 12:02PM
May-11-23 05:35PM
04:01PM
May-09-23 08:00AM
May-04-23 06:15PM
08:00AM
Apr-26-23 08:00AM
Apr-18-23 08:00AM
Apr-10-23 07:57PM
Mar-30-23 08:00AM
Mar-28-23 03:57PM
Mar-20-23 08:00AM
Mar-11-23 03:00AM
Mar-10-23 06:33AM
Mar-09-23 05:25PM
04:01PM
Mar-06-23 08:00AM
Mar-02-23 09:55AM
08:00AM
Feb-22-23 09:46AM
08:00AM
Feb-08-23 08:00AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-17-22 12:00PM
09:45AM
Nov-10-22 06:35PM
04:05PM
Nov-08-22 05:45PM
Nov-03-22 08:00AM
Oct-31-22 08:00AM
Oct-10-22 08:00AM
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Howe Jill AnnChief Financial OfficerNov 26 '24Buy0.5915,0008,85025,500Nov 26 04:58 PM
Samuel George A. IIIGeneral CounselNov 26 '24Buy0.6015,0009,00022,184Nov 26 04:55 PM
Mulroy Michael H.DirectorNov 22 '24Buy0.5740,00022,640298,555Nov 25 04:30 PM
Culley Brian MPresident and CEONov 21 '24Buy0.6040,00024,000194,842Nov 22 09:00 AM
Howe Jill AnnChief Financial OfficerAug 16 '24Buy0.8910,5009,34510,500Aug 19 06:24 PM
Culley Brian MPresident and CEOMay 24 '24Buy1.0510,00010,500154,842May 28 09:11 AM
BAILEY DON MDirectorFeb 08 '24Buy1.0496,155100,001158,801Feb 08 07:00 PM
BROADWOOD PARTNERS, L.P.DirectorFeb 06 '24Buy1.046,730,7707,000,00141,666,255Feb 08 06:58 PM
Jayasuriya AnulaDirectorDec 29 '23Buy1.0910,00010,90010,000Jan 02 07:08 PM